• Price Momentum

    LKFT is trading near the bottom of its 52-week range and below its 200-day simple moving average.

  • Price change

    The price of LKFT shares has decreased $0.43 since the market last closed. This is a 1.53% drop.

  • Closed at $27.72.

    The stock has remained unchanged in after-hours trading.

Key terms

About LKFT

Lakefront Biotherapeutics is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
  • Market cap: $1.62B

    A market capitalization between $300 million and $2 billion places LKFT in the small capitalization category.

Key terms

Smart score

Latest LKFT news

Jul 21, 2026 5:00pm ET Lakefront Biotherapeutics Buys Back 98,648 Shares Under Ongoing Repurchase Program Jul 13, 2026 4:57pm ET Lakefront Biotherapeutics Board Member Resigns After Sanofi R&D Appointment Jul 10, 2026 5:30am ET Lakefront Biotherapeutics resumed with an Equal Weight at Morgan Stanley Jul 10, 2026 5:25am ET Judah Frommer Maintains Hold on LKFT, Citing Early but Strategic Gamgertamig Acquisition and Limited Economic Upside Jul 07, 2026 4:47pm ET Lakefront Biotherapeutics Buys Back Over 104,000 Shares Under June 2026 Repurchase Program Jun 30, 2026 4:57pm ET Lakefront Biotherapeutics Details June Share Buybacks Under Ongoing Repurchase Program Jun 30, 2026 6:30am ET Lakefront Biotherapeutics Discloses New 5% Stake by Madison Avenue Partners Jun 24, 2026 6:28am ET Lakefront Biotherapeutics Buys Back 77,667 Shares Under June 2026 Repurchase Program Jun 16, 2026 6:11pm ET Lakefront Biotherapeutics Details June Share Buybacks Under New Repurchase Program Jun 09, 2026 4:13pm ET Lakefront Biotherapeutics announces EUR 50M share repurchase program Jun 08, 2026 4:13pm ET Lakefront Biotherapeutics appoints Eric Hedrick chief medical officer Jun 05, 2026 6:29am ET Lakefront Biotherapeutics and Gilead Close Ouro Medicines Deal, Anchor Autoimmune Pipeline Around Gamgertamig May 27, 2026 6:29am ET Lakefront Biotherapeutics Discloses Bank of America Building 9.3% Stake May 20, 2026 1:16am ET Lakefront Biotherapeutics Bets Big on Ouro Pivot May 14, 2026 12:30pm ET Dermatomyositis Trial Update Sets Context For LKFT’s Autoimmune Pipeline May 14, 2026 12:30pm ET Lakefront Biotherapeutics Spotlight: Completed Phase 2 Lupus Study Sets Stage for Key Data Catalyst May 13, 2026 7:47am ET RBC Capital Sticks to Its Hold Rating for Lakefront Biotherapeutics (LKFT)

No recent press releases are available for LKFT

LKFT Financials

1-year income & revenue

  • Total revenue: $1.25B (1Y), $7.58M (Q1)

    Total Revenue increased 320.99% since last year and decreased 99.28% since last quarter.

  • Net income: $362.14M (1Y), $16.25M (Q1)

    Net Income increased 351.92% since last year and decreased 98.22% since last quarter.

  • Earnings per share: $5.50 (1Y), $0.26 (Q1)

    EPS increased 351.91% since last year and decreased 98.14% since last quarter.

Key terms

LKFT Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

LKFT Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range
  • How competitors are chosen

    LKFT's competitors are included in the Health Technology sector and Biotechnology group

  • Market cap: $1.62B

    A market capitalization between $300 million and $2 billion places LKFT in the small capitalization category.

Key terms